The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings

2018 ◽  
pp. 47-65 ◽  
Author(s):  
Md. Shahidul Islam
Keyword(s):  
Heart Failure ◽  
Clinical Settings ◽  
Art And Science

692 A novel prognostic index including comorbidities for stable heart failure validated in different clinical settings

2006 ◽  
Vol 5 (1) ◽  
pp. 156-156
Author(s):  
M SENNI ◽  
G SANTILLI ◽  
P PARRELLA ◽  
R DEMARIA ◽  
G ALARI ◽  
...  
Keyword(s):  
Heart Failure ◽  
Prognostic Index ◽  
Clinical Settings

scholarly journals Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association

Circulation ◽  
2020 ◽  
Vol 141 (22) ◽  
Author(s):  
Lisa Kitko ◽  
Colleen K. McIlvennan ◽  
Julie T. Bidwell ◽  
J. Nicholas Dionne-Odom ◽  
Shannon M. Dunlay ◽  
...  
Keyword(s):  
Heart Failure ◽  
Family Caregiving ◽  
Heart Association ◽  
Well Being ◽  
Clinical Settings ◽  
Financial Health ◽  
Future Directions ◽  
Scientific Statement ◽  
The Relationship ◽  
Health And Well Being

Many individuals living with heart failure (HF) rely on unpaid support from their partners, family members, friends, or neighbors as caregivers to help manage their chronic disease. Given the advancements in treatments and devices for patients with HF, caregiving responsibilities have expanded in recent decades to include more intensive care for increasingly precarious patients with HF—tasks that would previously have been undertaken by healthcare professionals in clinical settings. The specific tasks of caregivers of patients with HF vary widely based on the patient’s symptoms and comorbidities, the relationship between patient and caregiver, and the complexity of the treatment regimen. Effects of caregiving on the caregiver and patient range from physical and psychological to financial. Therefore, it is critically important to understand the needs of caregivers to support the increasingly complex medical care they provide to patients living with HF. This scientific statement synthesizes the evidence pertaining to caregiving of adult individuals with HF in order to (1) characterize the HF caregiving role and how it changes with illness trajectory; (2) describe the financial, health, and well-being implications of caregiving in HF; (3) evaluate HF caregiving interventions to support caregiver and patient outcomes; (4) summarize existing policies and resources that support HF caregivers; and (5) identify knowledge gaps and future directions for providers, investigators, health systems, and policymakers.

scholarly journals Usefulness of Seattle Heart Failure Model in Heart Failure Patients with Reduced Ejection Fraction in the Clinical Settings

2015 ◽  
Vol 21 (10) ◽  
pp. S171
Author(s):  
Kotaro Miyaji ◽  
Sandeep Shakkya ◽  
Naoki Hayakawa ◽  
Hiroki Suzuki ◽  
Satoshi Kodera ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Clinical Settings ◽  
Failure Model ◽  
Reduced Ejection Fraction ◽  
Heart Failure Patients ◽  
Heart Failure Model

The effectiveness of CRT on improvement of survival of heart failure patients in real life clinical settings

2017 ◽  
Vol 72 (2) ◽  
pp. 180-187
Author(s):  
Marek Hudak ◽  
Michal Kerekanic ◽  
Silvia Misikova ◽  
Erika Komanova ◽  
Alexander Boho ◽  
...  
Keyword(s):  
Heart Failure ◽  
Real Life ◽  
Clinical Settings ◽  
Heart Failure Patients

Should all acutely ill medical patients be treated with antithrombotic drugs?

2013 ◽  
Vol 109 (04) ◽  
pp. 589-595 ◽  
Author(s):  
Ludovica Perri ◽  
Lorenzo Loffredo ◽  
Francesco Violi
Keyword(s):  
Heart Failure ◽  
Venous Thrombosis ◽  
Observational Studies ◽  
Risk Profile ◽  
Medical Illness ◽  
Clinical Settings ◽  
Medical Patients ◽  
Antithrombotic Drugs ◽  
Thrombotic Risk ◽  
Acute Infections

SummaryAfter reports from observational studies suggesting an association between acutely ill medical patients and venous thromboembolism (VTE), interventional trials with anticoagulants drugs have demonstrated a significant reduction of VTE during and immediately after hospitalisation. Although several guidelines suggest the clinical relevance of reducing this outcome, there is a low tendency to use anticoagulants in patients hospitalised for acute medical illness. We speculated that such underuse may be dependent on a low perception that patients included in the trials are actually at risk of thromboembolism. Therefore, the aim of this study was to analyse the clinical settings included in the interventional trials and their relationship with thrombotic risk. Analysis of interventional trials revealed that the majority of patients included in the trials (about 80%) were affected by heart failure, acute respiratory syndrome or infections. Among these three illnesses, literature data shows an association with venous thrombosis only in patients with acute infections; this finding was, however, supported only by retrospective study. On the contrary, there is scarce or no evidence that heart failure and acute respiratory syndrome are associated with venous thrombosis. These data underscore the need of better defining the thrombotic risk profile of acutely ill medical patients included in interventional trials with anticoagulants.

scholarly journals Rare Cause for Sudden Right Heart Failure

2010 ◽  
Vol 10 ◽  
pp. 1996-1998 ◽  
Author(s):  
Amir M. Nia ◽  
Natig Gassanov ◽  
Matthias Schmidt ◽  
Ferdinand Kuhn-Régnier ◽  
Erland Erdmann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Malignant Tumors ◽  
Right Heart Failure ◽  
Decompensated Heart Failure ◽  
Clinical Settings ◽  
Right Heart ◽  
Large Tumor ◽  
Multiple Metastases ◽  
The Right ◽  
Time Point

Right heart failure occurs daily in clinical settings, but an underlying cardiac malignant tumor is very uncommon. We report a case of a 48-year-old man presenting only with palpitations and decompensated heart failure. Echocardiographic imaging revealed a large tumor of the right ventricle. Shortly after a putatively successful surgical approach, the patient was admitted again with heart failure symptoms. On reassessment, a complete relapse with multiple metastases could be seen. Generally, cardiac malignant tumors are diagnosed at a time-point when therapeutic options are very limited or even postmortem. Broad echocardiographic screening in patients with unspecific symptoms might be helpful to detect cardiac malignant tumors at early stages.

scholarly journals Tachycardia-related cardiomyopathy: a review of the literature

2013 ◽  
pp. 92-98
Author(s):  
Maurizio Ongari ◽  
Giuseppe Boriani
Keyword(s):  
Heart Failure ◽  
Rate Control ◽  
Ventricular Dysfunction ◽  
Myocardial Dysfunction ◽  
Subsequent Development ◽  
Left Ventricular ◽  
Clinical Settings ◽  
Supraventricular Tachyarrhythmia ◽  
Ventricular Response ◽  
Supraventricular Tachyarrhythmias

A fast heart rate or an irregular ventricular rhythm can produce various degrees of functional impairment and structural remodeling of the ventricle referred to as tachycardiarelated cardiomyopathy or tachycardiomyopathy. This form of myocardial dysfunction can be caused by supraventricular or ventricular tachyarrhythmias that are incessant and associated with ventricular rates higher than 120 bpm. It can be reversed with pharmacological or nonpharmacological rate control or arrhythmia reversion. The prevalence of ventricular and supraventricular tachyarrhythmias is high among patients with heart failure. Consequently, in clinical settings, it may be difficult to determine whether a patient with severe ventricular dysfunction and supraventricular tachyarrhythmia associated with a rapid ventricular response is suffering from tachycardiomyopathy or from heart failure complicated by the subsequent development of a supraventricular tachyarrhythmia (e.g. atrial fibrillation). This typical ‘‘chicken-or-the-egg’’ dilemma can be resolved by treating the arrhythmia (pharmacological or nonpharmacological rate and/or rhythm control) and closely monitoring the evolution of the left ventricular dysfunction. Proper management of tachycardiomyopathy requires appropriate decision making, use of both pharmacological and nonpharmacological treatment approaches, and close follow-up. The purpose of this review article is to examine currently available data (experimental and clinical) on this complex clinical entity and on rate-control therapy.

scholarly journals Is galectin-3 a promoter of ventricular dysfunction?

2018 ◽  
Vol 26 (1) ◽  
pp. 21-36
Author(s):  
Adrian Lupu ◽  
Silvia Lupu ◽  
Lucia Agoston-Coldea
Keyword(s):  
Heart Failure ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Myocardial Inflammation ◽  
Clinical Settings ◽  
Comprehensive Overview ◽  
Prognostic Assessment ◽  
Patients With Heart Failure ◽  
Galectin 3

Abstract Heart failure is nowadays a common condition associated with high mortality and increased healthcare-related costs. Over the years, the research on heart failure management has been extensive in order to better diagnose and treat the condition. Since the progression of left ventricular dysfunction is a consequence of myocardial inflammation, apopotosis, and fibrosis leading to myocardium remodelling, several molecules that are involved in the inflammation pathways have been explored as possible biomarkers for the condition. The study of biomarkers and their key roles in inflammation could allow early identification of patients with heart failure, improve prognostic assessment, and provide a target for future therapies. Among currently studied biomarkers, extensive research has been conducted on galectin-3, a galactoside-binding lectin, which is synthetised and secreted when cardiomyocytes and fibroblasts are submitted to mechanical stress. Accordingly, it has been hypothesised that galectin-3 could be a promoter of left ventricular dysfunction. Galectin-3 has been shown to mediate inflammation by several different pathways which are further detailed in the current review. Also, we aimed to provide a comprehensive overview of existing evidence on the utility of galectin-3 in clinical settings associated with heart failure.

scholarly journals Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
K. Selthofer-Relatić ◽  
A. Kibel ◽  
D. Delić-Brkljačić ◽  
I. Bošnjak
Keyword(s):  
Heart Failure ◽  
Hypertensive Heart Disease ◽  
Visceral Obesity ◽  
Vascular Diseases ◽  
Clinical Settings ◽  
Special Role ◽  
Cardiac Cachexia ◽  
Reduced Ejection Fraction ◽  
Artery Disease ◽  
And Function

Obesity is a risk factor for cardiometabolic and vascular diseases like arterial hypertension, diabetes mellitus type 2, dyslipidaemia, and atherosclerosis. A special role in obesity-related syndromes is played by cardiac visceral obesity, which includes epicardial adipose tissue and intramyocardial fat, leading to cardiac steatosis; hypertensive heart disease; atherosclerosis of epicardial coronary artery disease; and ischemic cardiomyopathy, cardiac microcirculatory dysfunction, diabetic cardiomyopathy, and atrial fibrillation. Cardiac expression of these changes in any given patient is unique and multimodal, varying in clinical settings and level of expressed changes, with heart failure development depending on pathophysiological mechanisms with preserved, midrange, or reduced ejection fraction. Progressive heart failure with misbalanced metabolic and catabolic processes will change muscle, bone, and fat mass and function, with possible changes in the cardiac fat state from excessive accumulation to reduction and cardiac cachexia with a worse prognosis. The question we address is whether cardiac obesity or cardiac cachexia is to be more feared.

Sign in / Sign up

Export Citation Format

Share Document